PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18641551-1	2008	We aimed to evaluate the effects of cytochrome P450 (CYP) 2C19 and CYP3A5 polymorphisms on zonisamide (ZNS) clearance.	Zonisamide	91-101	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	67-73	
9626925-4	1998	RESULTS: From the experiments using ten expressed human CYPs, CYP2C19, CYP3A4 and CYP3A5 were shown to be capable of catalyzing zonisamide reduction.	Zonisamide	128-138	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	82-88	
9626925-12	1998	CONCLUSION: We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide.	Zonisamide	38-48	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	99-105